Navigation Links
Axelar's Board Strengthened
Date:4/27/2010

STOCKHOLM, April 27, 2010 /PRNewswire/ -- Axelar AB, a Karolinska Development portfolio company, today announces that Goran Pettersson has been elected new chairman of the board and Ingemar Kihlstrom board member. Both have vast international experience from leading positions in the pharmaceutical industry.

"We have just secured 25 MSEK financing for the continued development of Axelar's anticancer compound "AXL1717". It's encouraging that we at the same time are able to further strengthen the board with Goran and Ingemar, both having so much international experience from the pharmaceutical industry. They will contribute with valuable knowledge in the continued development of Axelar," says Johan Harmenberg, CEO Axelar AB.

Goran Pettersson has held leading positions in Astra, KabiVitrum, Pharmacia/PharmaciaUpJohn and Meda. Currently, he is also chairman of the board in Medivir AB, OxyPharma AB and Vivoxid Oy, and board member in Diamyd Medical AB, Pfizer Sweden Pensionsstiftelse and Recipharm AB.

Ingemar Kihlstrom has held leading positions in Pharmacia, Aros Securities and ABG Sundal Collier. He is currently serving as board member in a number of Scandinavian companies including being chairman of the board in Artimplant AB, Creative Antibiotics AB, Hammercap AB and RecoPharma AB, and vice chairman of the board in Diagenic ASA.

TO THE EDITORS

About Axelar

Axelar is a Swedish biotech company founded in 2003. The company is developing an insulin-like growth factor-1 (IGF-1) receptor inhibitor for cancer treatment. Axelar is part of the Karolinska Development portfolio. http://www.axelar.se

About AXL1717

Axelar's lead compound, AXL1717, provides a novel treatment for a wide range of cancers. AXL1717 is the first targeted oral small-molecule IGF-1 receptor inhibitor with no effect on the insulin receptor. AXL1717 is presently undergoing Phase I/II clinical trials and the compound combines a superior preclinical efficacy against numerous tumors with an excellent tolerability profile. Most tumor cells are dependent on the IGF-1 receptor signal pathway and the IGF-1 receptor is therefore regarded as an excellent target for cancer therapy. To date, there are no IGF-1 receptor inhibitor drugs on the market.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

    For further information, please contact:
    Johan Harmenberg, CEO, Axelar AB
    Phone: +46(0)705-14-54-53, e-mail: johan.harmenberg@axelar.se



'/>"/>
SOURCE Karolinska Development and Axelar
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
2. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
3. American Board of Internal Medicine President Named to Alzheimers Study Group
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
6. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
9. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
10. Silence Therapeutics Announces Board Changes
11. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):